Introduction
============

Total anomalous pulmonary venous connection (TAPVC) is a rare but heterogeneous congenital heart anomaly in which pulmonary veins do not connect routinely to the left atrium but abnormally connect to the right atrium or systemic venous system. The incidence of TAPVC is approximately 1 out of 15,000 live births ([@B1]; [@B3]; [@B33]). TAPVC is rare but without proper intervention in the first year of life the mortality of TAPVC is nearly 80% ([@B7]). However, the molecular mechanism of TAPVC remains unknown.

So far, only a few genes have been demonstrated as pathogenic genes for TAPVC and these genes are just a partial explanation for some patients. [@B5] used genetic linkage analysis found a locus for TAPVR at 4p13-q12 called total anomalous pulmonary venous return 1 (*TAPVR1*) and other important pathogenic genes in this region include vascular endothelial growth factorreceptor 2 (*VEGFR2*) and platelet-derived growth factor receptor α (*PDGFRA*). [@B23] used whole genome sequence to identify a non-synonymous variant in the retinol binding protein 5 (*RBP5*) gene which probably related to TAPVC. [@B17] considered activin A receptor type II-like 1 *(ACVRL1*) and sarcoglycan delta (*SGCD*) as TAPVC pathogenic genes using whole exome sequence from 6 TAPVC cases. However, these pathogenic genes explain only a small fraction of the molecular mechanism of TAPVC, the underlying cause in most patients remains unknown.

Copy number variant (CNV) is defined as a segment of DNA at least 1 kb in size that differs in copy number compared with a representative reference genome ([@B38]; [@B27]). CNVs have been shown to play an important role in the pathogenicity of complex birth defects ([@B12]). CNV, or submicroscopic chromosomal deletions or duplications, has emerged as an important contributor to congenital genetic disorders and has identified critical dosage sensitive genes important for cardiac development ([@B16]; [@B32]; [@B22]). Whether CNV detection could be as a genetic selection for novel pathogenesis genes of TAPVC is still not reported previously, and it needs to be further studied.

Materials and Methods {#s1}
=====================

Patient Ascertainment
---------------------

Our study recruited patients with TAPVC Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine whose diagnoses were confirmed by echocardiography, cardiac catheterization, computed tomography, and other medical recordings. Patients with multiple major developmental anomalies, developmental syndromes, or major cytogenetic abnormalities were excluded. Ethical approval was given by the medical ethics committee of Xinhua Hospital.

Detection of CNVs From WES Data
-------------------------------

Peripheral blood samples were obtained and DNA was extracted using the QIAamp DNA Blood Midi Kit (Qiagen, Germany). WES samples were captured with the Agilent Sure Select Target Enrichment kit (V6 58 Mb; Agilent Technologies, United States) and sequenced on the Illumina HiSeq 2500 platform ([@B11]; [@B18]). CNV coordinates were converted to the GRCh37/hg19 build using the UCSC Genome Browser LiftOver tool. CNVs with 50% or larger overlap with telomere, centromere, segmental duplications, or immunoglobulin regions were excluded ([@B13]). After filtering we screened out rare CNVs by comparing with the Database of Genomic Variants (DGV^[1](#fn01){ref-type="fn"}^) and Online Mendelian Inheritance in Man (OMIM^[2](#fn02){ref-type="fn"}^).

Identification of Pathogenic CNV Candidates
-------------------------------------------

The CNV regions were firstly annotated with RefSeq genes. For each gene and each sample, the copy number status was determined by the annotated CNV regions. The pathogenic CNV candidates were then identified by statistical comparisons between the case and control groups. The statistical comparisons between groups were analyzed by one-side Fisher's exact test with alternative hypothesis that the mutation frequency is greater in case group than the control group. The CNV candidates were defined as potentially pathogenic if the *P* \< 0.01. The analysis and visualization were implemented in R programming software with version 3.5.0.

Protein--Protein Interaction (PPI) Analysis
-------------------------------------------

Protein--Protein Interactions (PPI) are physical contacts with molecular associations between chains that occur in a cell or in a living organism in a specific biomolecular context ([@B10]). Our candidate pathogenic genes with CNVs, combined with 27 known disease-causing genes derived from the literature and publicly available database, were mapped to PPI network in STRING database^[3](#fn03){ref-type="fn"}^ ([@B6]), which identified the connections between the candidate pathogenic genes and the known disease-causing genes. Information found in STRING databases supports the construction of interaction networks ([@B20]).

Expression Patterns of the Selected Genes During Human Embryonic Heart Development
----------------------------------------------------------------------------------

Expression patterns of the human embryonic heart of candidate genes were detected using an Affymetrix HTA 2.0 microarray. To determine whether these candidate genes could affect human embryonic heart development, Carnegie stages 11 through 15 of human embryonic heart samples were collected from Xinhua hospital. RNA extraction used TissueLyser II (Qiagen, Germany) and the RNeasy MinElute Cleanup Kit (Qiagen, Germany) as previous study ([@B24]). The integrity and purity of the RNA was detected by the Experion automated gel electrophoresis system (Bio-Rad, United States) and the NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, United States).

Results
=======

Clinical Data
-------------

A total of 78 sporadic TAPVC cases and 100 healthy controls were recruited in our research. Among these patients, no one had central nervous system malformations, vertebral defects, or genitourinary malformations. The patients' ages ranged from 27 days to 7 years; 45 patients were male (57.7%) and 33 were female (42.3%). Among all these patients, 47 had atrial septal defect (ASD), 16 had patent foramen ovale (PFO), 10 had ventricular septal defect (VSD), and 16 had patent ductus arteriosus (PDA). Double outlet right ventricle (DORV) was discovered in three patients, atrioventricular septal defect in three patients. The detailed clinical data and cardiac phenotypes are summarized in Table [1](#T1){ref-type="table"}. All patients were recruited via Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and all signed an informed consent approved by the Ethics Committee of Xinhua Hospital.

###### 

The summary of 78 TAPVC patients.

  Patient characteristics                  Discovery cohort
  ---------------------------------------- ------------------
  Mean age at diagnosis (years)            0.95 ± 1.87
  BMI (kg/m^2^)                            14.92 ± 3.05
  Male (*n*, %)                            45(57.7)
  Mortality (*n*, %)                       4(5.1)
  **Associated cardiac lesion (*n*, %)**   
  ASD                                      57(73.7)
  PFO                                      16(20.5)
  VSD                                      10(12.8)
  PDA                                      16(20.5)
  DORV                                     3(3.8)
  AVSD                                     3(3.8)

CNVs in Patients With TAPVC and Identification of Candidate Genes
-----------------------------------------------------------------

To discover the pathogenic CNV candidates, we identified WES data by statistical comparisons between the case and control groups. We use circos plot for CNV visualization with broad horizontal area from chromosome level (Figure [1](#F1){ref-type="fig"}). In all chromosomes, chromosome 1 had the most CNV numbers than other in our patients.

![A whole-genome view of copy number variations in case and control groups. Circos plot for variants visualization with broad horizontal area from chromosome level. The outer, middle, and inner tracks display the chromosomes, CNV frequency in case group, and CNV frequency in control group. The lines above or under zero represent gain or loss.](fgene-09-00559-g001){#F1}

Based on these data, we identified statistically significant CNVs at different genomic loci. CNVs were filtered as potentially pathogenic if the *P* \< 0.01 (Table [2](#T2){ref-type="table"}). Finally, we identified eight potentially pathogenic CNVs of seven genes (*PCSK7, RRP7A, SERHL, TARP, TTN, SERHL2, and NBPF3*) among 45 patients with TAPVC (Figure [2](#F2){ref-type="fig"}). The percentage of subjects with CNVs candidates was 58.4% (45 of 78 TAPVC subjects).

###### 

Copy number variant (CNV) detected by Fisher' test.

  CNV           Chromosome   Gene       Case with CNV   *P*-value
  ------------- ------------ ---------- --------------- -----------
  Duplication   Chr1         PCSK7      9               0.00040
  Duplication   Chr22        RRP7A      7               0.00241
  Duplication   Chr22        SERHL      7               0.00241
  Duplication   Chr7         TARP       13              0.00394
  Deletion      Chr2         TTN        8               0.00584
  Duplication   Chr22        SERHL2     6               0.00584
  Duplication   Chr1         NBPF3      6               0.00584
  Deletion      Chr1         PCSK7      6               0.00584
  Duplication   Chr17        KRTAP9-6   7               0.01239
  Deletion      Chr2         TTN-AS1    5               0.01404
  Duplication   Chr7         MTRNR2L6   5               0.01404
  Deletion      Chr20        FER1L4     8               0.01818
  Deletion      Chr1         FLG2       15              0.02036
  Deletion      Chr1         FLG-AS1    15              0.02036
  Deletion      Chr19        ZNF844     9               0.02292
  Deletion      Chr1         CROCC      6               0.02292
  Deletion      Chr1         OR2L5      6               0.02643
  Deletion      Chr1         SPATA21    4               0.03347
  Deletion      Chr1         RPTN       4               0.03347
  Deletion      Chr11        AHNAK      10              0.03347
  Deletion      ChrX         DMD        4               0.03347
  Duplication   Chr3         MUC4       4               0.03347
  Duplication   Chr16        STX4       4               0.03347
  Deletion      Chr22        GGT3P      4               0.03347
  Deletion      Chr1         OR2L3      4               0.03347
  Deletion      Chr19        ZNF611     4               0.03347
  Duplication   Chr10        ANTXRL     8               0.04273

![Manhattan plot of CNVs detected by whole exome sequencing. CNVs detection by statistical comparisons between the case and control groups. Different colors of points mean CNVs from different chromosome. *P* \> 0 means duplication while *P* \< 0 means deletion.](fgene-09-00559-g002){#F2}

Expression Pattern in Human Embryonic Heart
-------------------------------------------

We then detected the time course expression patterns of the candidate genes during different Carnegie stages of human heart development using microarray (Table [3](#T3){ref-type="table"}). Expression of *TNN* in human embryonic hearts had a significantly higher level than other genes. Expression of *PCSK7*, *RRP7A*, and *NBPF3* were also high just behind *TNN.*

###### 

Expression patterns of candidate genes in human embryonic hearts at different time points.

  Chromosome   Gene     S10     S11     S12     S13     S14     S15     S16
  ------------ -------- ------- ------- ------- ------- ------- ------- -------
  chr12        GAPDH    17.47   17.50   17.48   17.45   17.35   17.24   17.00
  chr11        PCSK7    7.01    7.04    7.05    7.07    7.18    7.17    7.05
  chr22        RRP7A    7.00    6.93    7.03    6.69    7.05    6.93    6.88
  chr22        SERHL    4.96    5.02    4.87    4.93    4.85    5.02    4.93
  chr7         TARP     3.76    3.69    3.58    3.69    3.69    3.69    3.69
  chr2         TTN      15.74   17.84   18.00   17.83   17.82   17.85   17.77
  chr22        SERHL2   5.09    5.10    5.07    5.10    5.10    5.10    5.10
  chr1         NBPF3    7.12    7.11    7.14    7.08    7.14    7.16    7.14

STRING Network Analysis
-----------------------

We got 27 known pathogenic genes derived from the literature and publicly database. Then we used STRING database to explore the PPI network between CNV candidate genes and known pathogenic genes. Through PPI network, we found *PCSK7* and *TTN* had more direct and obvious relation to known pathogenic genes (Figure [3](#F3){ref-type="fig"}). *PCSK7* directly interacts with *KDR* and *TTN* indirectly interacts with *ANKRD1* and *SGCD*. These two genes could interact with other pathogenic genes via several other genes.

![Protein--protein interaction between candidate genes and known genes. STRING networks included 27 genes previously associated to TAPVC and 7 candidate genes highlighted by CNV detection analysis.](fgene-09-00559-g003){#F3}

Discussion
==========

Total anomalous pulmonary venous connection is a rare congenital heart defect characterized by the misconnection of all four pulmonary veins, which could cause severe morbidity and mortality ([@B4]). Several genes have been associated TAPVC but the etiology of TAPVC is still complicated. To detect the underlying mechanism of TAPVC, we screened a cohort of 78 TAPVC cases and 100 healthy controls for rare CNVs and novel candidate genes, using whole exome sequencing (WES). Then we got seven totally novel candidate genes (*PCSK7, RRP7A, SERHL, TARP, TTN, SERHL2, and NBPF3*) that were associated with TAPVC. STRING network analysis demonstrated that *PCSK7* and *TTN* which are highly related to known pathogenic genes, appear to play an important role in the genetic mechanism of TAPVC.

Both deletion and duplication of CNV could have been associated with congenital disorders ([@B21]). Recent data show that the frequency of duplications is approximately half of deletions and their phenotypes of heart malformation are much more diverse. It is possible that genomic deletions are more likely to cause dosage sensitivity compared with duplications because the fold change is greater for deletions. In seven candidate genes, we found deletion CNVs only in *PCSK7* and *TTN.*

A total of 9 (9/78, 11.5%) patients had duplication and 6 (6/78, 7.7%) patients had deletion in *PCSK7*. *PCSK7* (Proprotein convertase subtilisin/kexin type 7) is a member of the subtilisin-like proprotein convertase family ([@B9]). The genetic regulation of PCSK expression especially *PCSK7* could bind to other genes to make huge impact on the blood pressure ([@B26]; [@B34]). Recent research of cardiovascular Disease (CVD) network using 1512 SNPs associated with 21 traits in genome-wide association showed *PCSK7* connected closely to the incidence of CVD ([@B39]). In our study, 8 (8/78, 10.3%) patients were detected to have the deletion in *TTN.TTN* (Titin) encodes the sarcomere protein titin. Among its related pathways are dilated cardiomyopathy (DCM) and cardiac conduction ([@B15]). A large literature suggested that majority of familial and sporadic DCM had the rare variants in *TTN* ([@B14]; [@B37]). A study found *TTN* and *ANKRD1* which was an important pathogenic gene of TAPVC could combine to cause DCM ([@B2]). And expression of *TNN* and *PCSK7* were higher than other genes in human embryonic hearts. Above all, *PCSK7* and *TTN* can be a totally novel candidate gene for TAPVC pathogenesis but the underlying mechanism remains unclear.

We found seven patients had duplications in *SERHL*, *RRP7A* and six patients in *SERHL2. SERHL*, *SERHL2*, and *RRP7A*, these genes are all located on chromosome 22q13. *SERHL* (Serine hydrolase-like) was encoded within the mRNA is an open reading frame of 311 amino acids which shows identity to a family of serine hydrolases ([@B30]). *SERHL* was found in tetralogy of Fallot patients and was associated with DNA methylation abnormalities ([@B31]). *SERHL2* also belongs to the serine hydrolase family, while its functional role is yet to be elucidated, and other nearby genes in the region, such as *RRP7A*, could also be biological candidates linked to 22q13 deletion syndrome ([@B25]). Patients with 22q13 duplication have been reported to have the clinical diagnosis of cardiovascular abnormalities and intrauterine growth restriction ([@B8]; [@B28]). The relationship between *RRP7A, SERHL*, and *SERHL2* and TAPVC needs to be further validated experimentally. Thus far, the functions of these genes in cardiovascular development remain unknown, and they be might newly associated with TAPVC pathogenesis.

In our research, *TARP* had the most patients than other genes, 13 (13/78, 16.7%) patients with duplication was detected in *TARP.TARP* (TCR gamma alternate reading frame protein) which is a marker for T cells and NKT cells and uniquely expressed in males in prostate epithelial cells and prostate cancer cells ([@B19]). It has been reported to be a biomarker for viral myocarditis ([@B29]). We also found 6 (6/78, 7.7%) patients had duplication in *NBPF3.NBPF3* (NBPF member 3) is a member of the neuroblastoma breakpoint family (NBPF) which consists of dozens of recently duplicated genes primarily located in segmental duplications on human chromosome 1 ([@B36]). NBPF3 is reported to express in a variety of tissues ([@B35]). Our study is flawed. First, the lack of parental samples limited our ability to study the genetic backgrounds of the variants. Second, we lack the information of prognosis of TAPVC cases. In addition, the functions of our candidate genes need to be further verified with fundamental research. In summary, an effective analytical bioinformatics strategy allowed us to identify CNVs in novel genes that play a vital role in TAPVC pathology. Based on the results of CNV discovery in a case-control cohort, our study found evidence that CNVs of seven candidate genes (*PCSK7, RRP7A, SERHL, TARP, TTN, SERHL2, and NBPF3*) could contribute to the genetic etiology of TAPVC. Our candidate genes open new fields of investigation into TAPVC pathology and provide novel insights into pulmonary vein development.
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